Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide

Abstract Most soft-tissue sarcomas (STS) exhibit an immunosuppressive tumor microenvironment (TME), leading to resistance against immune checkpoint inhibitors (ICIs) and limited therapeutic response. Preclinical data suggest that oncolytic viral therapy can remodel the TME, facilitating T cell accum...

Full description

Bibliographic Details
Main Authors: Maud Toulmonde, Jean-Philippe Guegan, Mariella Spalato-Ceruso, Florent Peyraud, Michèle Kind, Lucile Vanhersecke, François Le Loarer, Raul Perret, Coralie Cantarel, Carine Bellera, Alban Bessede, Antoine Italiano
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Molecular Cancer
Subjects:
Soft-tissue sarcoma
Oncolytic virus
JX-594
Low-dose cyclophosphamide
Avelumab
Online Access:https://doi.org/10.1186/s12943-024-01946-8

Internet

https://doi.org/10.1186/s12943-024-01946-8

Similar Items